Cost–effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal

References

• American Heart Association. Heart Disease and Stroke Statistics—2003. Update. Dallas, TX: American Heart Association, 2003
   Google Scholar
• Instituto Nacional de Estatistica, Statistics Portugal. portuguese Life Table 2007–2009. http://www.ine.pt/. Accessed October 1, 2013
   Google Scholar
• Soini EJ, Davies G, Martikainen JA, et al. Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland. Curr Med Res Opin 2010;26:25-36
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;13;376:1670-81
   Google Scholar
• Reckless J, Davies G, Tunceli K, et al. Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study. Value Health 2010;13:726-34
   PubMed Web of Science ®Google Scholar
• da Silva PM, Cardoso SM. Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS). Rev Port Cardiol 2011;30:47-63
   PubMedGoogle Scholar
• Stein E, Stender S, Mata P, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004;148:447-55
   PubMed Web of Science ®Google Scholar
• Schuster H, Barter PJ, Stender S, et al. Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (Mercury I) study. Am Heart Journal 2004;147:705-12
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bertolami M, Hernandez Garcia HR, et al. Achieving LDL cholesterol, non-hdl cholesterol and apolipoprotein B target levels in high-risk patients: measuring effective reductions in cholesterol using rosuvastatin therapy (Mercury II). Am Heart J 2006;151:975.e1
   PubMed Web of Science ®Google Scholar
• Bullano MF, Wertz DA, Yang GW, et al. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy 2006;26:469-78.17
   PubMed Web of Science ®Google Scholar
• Bullano MF, Kamat S, Wertz DA, et al. Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density lipoprotein cholesterol goals in a usual care setting. Am J Health Syst Pharm 2007;64:276-84
   PubMed Web of Science ®Google Scholar
• Fox KM, Gandhi SK, Ohsfeldt RL, et al. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting. Am J Manag Care 2007;13(10 Suppl):S270-5
   Google Scholar
• Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008;156:826-32
   PubMed Web of Science ®Google Scholar
• Cannon CP. IMPROVE-IT trial: a comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Chicago, IL: American Heart Association Scientific Sessions, 2014
   Google Scholar
• Cook JR, Yin D, Alemao E, et al. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia. Pharmacoeconomics 2004;22(3 Suppl):37-48
   Google Scholar
• Cook JR, Yin D, Alemao E, et al. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal. Application to Germany, Spain and Norway. Pharmacoeconomics 2004;22(3 Suppl):49-61
   Google Scholar
• van Nooten F1, Davies GM, Jukema JW, et al. Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia. Neth Heart J 2011;19:61-7
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP). Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143
   PubMed Web of Science ®Google Scholar
• Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818
   PubMed Web of Science ®Google Scholar
• D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham Study. Am Heart J 2000;139:272-81
   PubMed Web of Science ®Google Scholar
• Goodacre S, Nicholl J, Dixon S, et al. Randomized controlled trial and economic evaluation of a chest pain observation unit compared with routine care. Br Med J 2004;7434:254-7
   Google Scholar
• McCormack T, Harvey P, Gaunt R, et al. IN-PRACTICE study Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. Int J Clin Pract 2010;64:1052-61
   PubMed Web of Science ®Google Scholar
• Melsop KA, Boothroyd DB, Hlatky MA. Quality of life and time trade-off utility measures in patients with coronary artery disease. Am Heart J 2003;145:36-41
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events. http://www.nice.org.uk/TA094. Accessed August 13, 2013
   Google Scholar
• Infarmed, Prontuário Terapêutico On-Line. 2015. http://www.infarmed.pt/prontuario/index.php. Accessed February 1, 2015
   Google Scholar
• Ministério da Saúde, Diário da República - I Série, n° 21 (Portaria n° 20/2014) de 29 de Janeiro de 2014
   Google Scholar
• Pereira R, Gouveia M, Martins AP. Análise custo-efectividade de sitaglipina quando adicionada a metformina em doentes com diabetes tipo 2 em Portugal. Revista Portuguesa de Diabetes 2012;7:13-23
   Google Scholar
• Ara R, Pandor A, Tumur I, et al. Estimating health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries. Clin Therapeut 2008;30:1508-23
   PubMed Web of Science ®Google Scholar
• Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92
   PubMed Web of Science ®Google Scholar